Developing next-generation hemophilia products for patients in need 

Essential Medicines for Hemophilia
Greater Convenience
Superior Outcomes

A leader in the field of engineered protease biopharmaceuticals 

Essential Medicines for Hemophilia
Greater Convenience
Superior Outcomes

Engineering proteases to improve the lives of patients

Essential Medicines for Hemophilia
Greater Convenience
Superior Outcomes

Next Generation Hemostasis Programs

Learn more about our Pipeline

FVIIa: marzeptacog alfa (activated)*
Hemophilia A or B with Inhibitors
Phase 2/3
FIX: dalcinonacog alfa**
Hemophilia B
Phase 1/2
FXa
Universal Pro-coagulant
Research

*(formerly known as CB 813d) / **(formerly known as CB 2679d/ISU304

Learn more about our Factor VIIa marzeptacog alfa (activated) trial

The Catalyst Advantage

Drug candidates for severe medical conditions

Learn more about the medicines we are developing

See our Pipeline

Addressing diseases with unmet medical needs

Share our passion about treating disease

Learn more about Hemophilia

We have an experienced and passionate team

Learn more about the Catalyst team and mission/culture

Meet the team